Free Newsletter
FDA approves Angiotech's Hemo-Stream
Free newsletter via e-mail
Tools
Angiotech has added one more brick to its stable of end stage renal disease treatment products. The company today got FDA clearance to sell a chronic dialysis catheter it licensed from Rex Medical in April. Known as Hemo-Stream, the catheter is designed to increase flow rates and cut the risk of complications such as embolism and bleeding.
Angiotech previously acquired a related vascular graft business, and it's enrolling for European trials of its Vascular Wrap AV product, a drug-coated device designed to keep permanent dialysis access points open.
- read the release for more info
Related Articles:
Angiotech buys Quill Medical. Report
CombinatoRx gains $7M from extended Angiotech pact. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: